1. Cibus welcomes EU's agreement on gene editing regulations. 2. New framework supports gene-edited plant development in Europe. 3. Cibus completed successful field trials in the UK. 4. EU NGT legislation enhances opportunities for Cibus's trait development. 5. Cibus addresses major agricultural challenges with innovative solutions.
FAQ
Why Bullish?
Cibus's commitment to developing traits increases with favorable EU regulations, enhancing growth potential.
How important is it?
The article highlights critical regulatory advancements directly favoring Cibus's strategic goals in Europe.
Why Long Term?
The new EU framework will facilitate future product launches and market adoption, benefiting Cibus’s long-term strategy.
Cibus Celebrates Milestone in EU Gene Editing Legislation Negotiations
On December 11, 2025, Cibus, Inc. (Nasdaq: CBUS) announced a significant advancement in the agricultural sector following the conclusion of trilogue negotiations on New Genomic Techniques (NGTs) within the European Union (EU).
Key Developments in New Genomic Techniques Legislation
The recent political agreement regarding NGTs signifies a pivotal change in plant breeding regulations in the EU, enabling a more science-based approach to innovation. This development, facilitated by a coalition of 26 agri-food organizations, aims to establish a comprehensive regulatory framework for gene-edited plants, addressing essential issues related to intellectual property and seed access.
The legislative text will now undergo formal endorsement by both the European Parliament and Council, marking a critical step forward for Cibus and the broader agricultural community.
Implications for Cibus and the Agricultural Community
Peter Beetham, PhD, Co-Founder and Interim CEO of Cibus, expressed optimism about the agreement, stating, “This agreement solidifies the European Union’s commitment to embracing gene editing technology and opens the door for the development of improved plant varieties for the European market.” This sentiment aligns with the company's strategic focus on providing high-value traits for European growers.
The trilogue negotiations showcased the effective leadership of the Danish Council Presidency and European Parliament lead rapporteur Jessica Polfjärd, whose dedication was instrumental in reaching this agreement.
Anticipated Market Impact and Future Opportunities
The agreement aligns with the United Kingdom's recent introduction of a similar regulatory framework for gene editing, which became effective on November 13, 2025. In anticipation, Cibus has already conducted successful field trials in the UK for its advanced trait pod shatter reduction in winter oilseed rape, demonstrating readiness to leverage new opportunities in the EU.
Tony Moran, Senior VP of International Development and Government Affairs at Cibus, remarked, “This is a pivotal moment for Cibus and our partners who have been working to develop improved plant varieties in anticipation of regulatory clarity in the EU.” The company aims to utilize this momentum to further enhance their product pipeline, which includes initiatives for disease resistance and nitrogen use efficiency.
About Cibus
Cibus is at the forefront of developing gene-edited productivity traits that tackle critical farming challenges such as diseases and pests, which the United Nations estimates costs the global economy approximately $300 billion annually. Unlike traditional seed companies, Cibus is a technology firm specializing in high-throughput gene editing technology, enabling rapid development and licensing of traits to seed companies in exchange for royalties on seed sales.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Cibus’ operational strategy, financial performance, and the anticipated impact of the EU’s NGT legislation. Factors such as competition, intellectual property challenges, and changes in market conditions may affect actual results.